Cancer has highly developed mechanisms in which it can evade the immune response. Very important to understand: HPV vaccine used to provide immunity against the virus, which causes cervical cancer. Traditional prophylactic vaccines, usually given in childhood to provide immunity against a particular disease. These involve the production of antibodies. HPV vaccine also involves production of antibodies. Majority of cancer vaccines are given to someone already affected by the disease, cancer. Involve the induction of a T-cell response.
Epitope: specific site on the tumor cell that is recognized by the immune system.
Gene Therapy: Lasting Expression of antigen is achieved by introduction of genetic material into dendritic cell.
Relative risk reduction (RRR): the extent to which a treatment reduces a risk, in comparison with patients not receiving the treatment of interest (ie., the percent reduction in events in treated compared to controls: RRR=[(CER-EER)/CER]).
Medical need great 30,000 deaths a year from this cancer. Most common noncutaneous cancer in men.
Non small cell lung cancer main cause of cancer death in men and women worldwide.
Hurdles: Not harming normal cells while still effectively treating the cancer. Eliciting an immune response that is effective enough to fight the cancer. Overcoming body’s mechanisms that allow tumor to evade immune response.
Armstrong ACª, Eaton D, Ewing JC. Cellular immunity for cancer. British Medical Journal. 2001;323:1289-1293. PMID 11731394.
Armstrong AC b , Hawkins RE. Vaccines in oncology: background and clinical potential. The British Journal of Radiology. 2001;74: 991-1002. PMID 11709463.
Berzofsky JA, Terabe M, Oh S, Belyakov IM, Ahlers JD, Janik JE, et al. Progess on new vaccine strategies for the immunotherapy and prevention of cancer. J. Clin. Interest. 2004; 113:1515-1525. PMID 15173875.
Blattman JN., Greenberg PD. Cancer immunotherapy: A treatment for the masses. Science. 2004;305:200-205. PMID 15247469.
Brand TC, Tolcher AW. Management of high risk metastatic prostate cancer: the case for novel therapies. The Journal of Urology. 2006;176: S76-S80. PMID 17084174.
Cancer.org. [homepage on the Internet]. Atlanta: American Cancer Society, Inc.; c2006. [revised 2005 April 11]. Available from http://www.cancer.org/
Dendreon.com [homepage on the Internet]. Seattle: Dendreon Corporation c2006.
Available from http://www. dendreon .com/
Department of Microbiology, Immunology, and Molecular Genetics Faculty Listing. Yannelli JR. University of Kentucky Chandler Medical Center c2004. Available from http://www.mc.uky.edu/microbiology/yannelli.asp
Goldsby RA, Kindt TJ, Osborne BA, Kuby Janis. Immunology. Fifth Ed. New York: W.H. Freeman and Company; 2003.
Groot CA, Vermorken JB, Hanna Jr MG, Verboom P, Groot MT, GJ Bonsel, et al. Immunotherapy with autologous tumor cell-BCG vaccine in patients with colon cancer: a prospective study of medical and economic benefits. ScienceDirect. 2005;23: 2379-2387.
Hirschowitz EA, Foody T, Krysico R, Dickson L, Sturgill J, Yannelli J. Autolougous dendritic cell vaccines for non-small-cell lung cancer. Journal of Clinical Oncology. 2004;22: 2808-2815.
Intracel.com. [homepage on the Internet] Frederick: Intracel Corporation c2006. Available from http://www. intracel .com/
Tabi Z a , Mann S. Challenges for cancer vaccine development. Science Direct. Advanced Drug Delivery Reviews. In press 2006.
Tabi Z b , Mann S. Human Cancer vaccines. Science Direct. Advanced Drug Delivery Reviews. In press 2006.
Tarassoff CP, Arlen PM, Gulley JL. Therapeutic vaccines for prostate cancer. The Oncologist. 2006;11:451-462. PMID 16720845.